Ace Therapeutics, a contract research organization specializing in translational blood disorder research, has launched a full-scale suite of integrated preclinical hematology CRO services designed to accelerate the discovery and regulatory advancement of novel therapeutics for hematologic diseases. The announcement, made on June 26, 2026, highlights the company's expanded collection of in vivo hematologic disease models and end-to-end study capabilities.
Hematologic diseases encompass complex pathologies affecting red blood cells, white blood cells, platelets, bone marrow, and lymphatic systems, including inherited anemias, autoimmune conditions, coagulation defects, myelodysplastic syndromes, and hematopoietic failure disorders. Traditional preclinical research often faces limitations in model translatability and study execution, creating bottlenecks for developers of gene therapies, biologics, small molecules, RNA modalities, and cell-based treatments. Ace Therapeutics addresses these challenges through vertically integrated services that unify in vitro modeling, in vivo efficacy testing, biomarker profiling, PK/PD analysis, safety toxicology, and custom biospecimen analytics.
The company's model bank includes genetically engineered lines, chemically induced disease platforms, antibody-triggered autoimmune systems, and patient-derived xenograft constructs. For genetic disorders, Ace Therapeutics maintains transgenic and knockout mouse models for sickle cell disease, α- and β-thalassemia, G6PD deficiency, and hereditary spherocytosis. Researchers studying bone marrow failure can access radiation or cyclophosphamide-induced myelosuppression rodents, immune-mediated aplastic anemia lymphocyte transfer models, and FANCA-knockout Fanconi anemia lines.
In addition to in vivo models, Ace Therapeutics offers cutting-edge in vitro platforms, including biomimetic 3D hematopoietic culture systems that reconstruct bone marrow niche microenvironments, patient-specific iPSC-derived hematopoietic disease lines, and functional assays using primary human CD34+ hematopoietic stem and progenitor cells. These tools enable high-throughput, human-relevant mechanistic research.
Services extend across the full drug development lifecycle, from target identification and CRISPR-based validation to specialized PK/PD profiling and safety pharmacology assessments. Evaluations focus on impacts on hematopoiesis, clotting function, endothelial integrity, and organ toxicity in blood-rich tissues like the spleen and bone marrow. Support is available for all therapeutic modalities, including small-molecule iron chelators, JAK inhibitors, monoclonal antibodies, LNPs delivering RNA therapeutics, AAV/lentiviral gene vectors, and engineered cell therapies.
All research workflows adhere to standardized operating procedures with rigorous quality control to ensure reproducible, regulatory-ready data. Clients can also collaborate on customized programs, including custom CRISPR-edited animal lines, humanized hematopoietic models, and niche-focused co-culture systems for rare conditions.
This launch is significant because it provides biotech and pharmaceutical developers with a single, integrated partner for preclinical hematology research, potentially reducing timelines and improving translatability of findings. As the field advances toward complex therapies for blood disorders, having validated models and comprehensive services could accelerate the path to clinical trials and, ultimately, new treatments for patients.
